VSTM

Announcements

Nothing here yet

Daily updates

• Verastem Oncology reported updated Phase 2 RAMP 201 and real-world external-control data for avutometinib plus defactinib in recurrent LGSOC. The regimen showed activity beyond traditional KRAS-mutant disease, including an 18% ORR and 13-month mPFS in KRAS/NRAS/BRAF triple-wild-type LGSOC and a 22% ORR in NRAS- or BRAF-mutated tumors without KRAS alterations. Propensity-weighted analyses showed improved response and durability versus current standards across KRAS-mutant and wild-type cohorts.Oct 2, 2026

FDA designations

• Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic CancerJul 24, 2025

News

• VS-7375 shows strong anti-tumor activity across advanced KRAS G12D-mutant cancers, with a 50% confirmed ORR in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line or later disease, one confirmedOct 14, 2026
• Verastem Oncology doses first patient in the TARGET-D 203 Phase 2 registration-directed trial of VS-7375Jul 29, 2026
• Verastem Oncology doses the first patient in the Phase 2 TARGET-D 202 registration-directed trial of VS-7375Jul 23, 2026
• VS-7375 demonstrated clinical activity and favorable tolerability in the Phase 1/2 TARGET-D 101 trialJun 24, 2026
• Verastem Oncology reported positive updated results from the RAMP 205 study of avutometinib plus defactinib with standard chemotherapy in first-line metastatic pancreatic cancerJun 17, 2026